With the announcement of clinical studies currently being developed for the new generation of Lyme vaccines and the results currently in progress of being reported, Dr. Morales decided to jump on this topic and address some of the most noted controversies, misconceptions and concerns revolving around this subject.

The 2020 Lyme vaccine is based from the same OspA recombinant technology of its predecessors. The prudent thing to do would be to have an open discussion among the scientists of both sides of the fence of the government, private corporations and recognized Lyme societies, addressing previous and newly arisen concerns. The scientists involved in the project should understand and acknowledge the intricacies of the disease, its immune deregulatory effects, chronicity forms, persisting mechanisms, polymorphism, genetics, cycles and sub-cycles as well as the consequences from the illness before undertaking such an endeavor. We should try to avoid, at all costs, the common dealings among big pharmaceuticals to create a poorly tested and studied product used for human use, have it run for 3-5 years - making huge profits - and then finding out it doesn’t work and deciding to pull it off the market when the pockets are full and candidates have been left afflicted or worse.

Please feel free to reach out to us if you have any questions or comments about this controversial topic - [email protected].